NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed Clinical Genomics' biomarkers associated with colorectal cancer in order to develop them as a detection tool, Clinical Genomics said today.

Under the two-year agreement, Clinical Genomics will receive milestone payments to allow Quest Diagnostics to develop the gene-based portfolio to detect precancerous and cancerous colorectal tumors. Quest's rights under the pact are worldwide and exclusive.

Quest Diagnostics also made an equity investment in Clinical Genomics of an undisclosed sum.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.